IL163911A0 - Naltrexone hydrochloride compositions - Google Patents

Naltrexone hydrochloride compositions

Info

Publication number
IL163911A0
IL163911A0 IL16391103A IL16391103A IL163911A0 IL 163911 A0 IL163911 A0 IL 163911A0 IL 16391103 A IL16391103 A IL 16391103A IL 16391103 A IL16391103 A IL 16391103A IL 163911 A0 IL163911 A0 IL 163911A0
Authority
IL
Israel
Prior art keywords
naltrexone hydrochloride
hydrochloride compositions
compositions
naltrexone
stabilizing
Prior art date
Application number
IL16391103A
Other languages
English (en)
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of IL163911A0 publication Critical patent/IL163911A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
IL16391103A 2002-03-14 2003-03-14 Naltrexone hydrochloride compositions IL163911A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36452102P 2002-03-14 2002-03-14
PCT/US2003/007932 WO2003077867A2 (en) 2002-03-14 2003-03-14 Naltrexone hydrochloride compositions

Publications (1)

Publication Number Publication Date
IL163911A0 true IL163911A0 (en) 2005-12-18

Family

ID=28041930

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16391103A IL163911A0 (en) 2002-03-14 2003-03-14 Naltrexone hydrochloride compositions

Country Status (15)

Country Link
US (2) US20030229111A1 (ko)
EP (2) EP1482912B1 (ko)
JP (2) JP4683842B2 (ko)
KR (1) KR20040098660A (ko)
CN (1) CN1652752A (ko)
AT (1) ATE510534T1 (ko)
AU (1) AU2003220290B2 (ko)
BR (1) BR0308452A (ko)
CA (2) CA2748620C (ko)
CO (1) CO5611137A2 (ko)
ES (1) ES2616981T3 (ko)
IL (1) IL163911A0 (ko)
MX (1) MXPA04008772A (ko)
RU (1) RU2004130441A (ko)
WO (1) WO2003077867A2 (ko)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL193273B1 (pl) 1997-12-22 2007-01-31 Euro Celtique Sa Postać dawkowania doustnego
CN1423559A (zh) 2000-02-08 2003-06-11 欧罗赛铁克股份有限公司 包含阿片样激动剂和拮抗剂的控释组合物
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
CA2478523A1 (en) 2002-04-05 2003-10-16 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
CN1674873A (zh) * 2002-08-15 2005-09-28 欧罗赛铁克股份有限公司 药物组合物
PL2368553T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
MXPA06003392A (es) * 2003-09-25 2006-06-08 Euro Celtique Sa Combinacion farmaceutica de hidrocodona y naltrexona.
JP2007530684A (ja) * 2004-03-30 2007-11-01 ユーロ−セルティーク エス．エイ． 吸着剤と逆作用薬とを含有する不正使用防止投与剤型
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US8465776B2 (en) 2006-08-04 2013-06-18 Ethypharm Granule and orally disintegrating tablet comprising oxycodone
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
ES2540551T3 (es) 2007-03-29 2015-07-10 Wyeth Llc Antagonistas de receptores opioides periféricos y usos de los mismos
AU2008233129B2 (en) 2007-03-29 2014-03-20 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
KR101491656B1 (ko) 2007-04-26 2015-02-09 도레이 카부시키가이샤 4,5-에폭시모르피난 유도체를 함유하는 안정한 고형 제제
WO2008143240A1 (ja) * 2007-05-21 2008-11-27 Toray Industries, Inc. 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
WO2010002576A1 (en) 2008-07-01 2010-01-07 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CN101658489B (zh) * 2008-08-27 2011-11-23 海南四环心脑血管药物研究院有限公司 一种盐酸纳美芬注射液及其制备方法
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
ES2660001T3 (es) 2008-10-24 2018-03-20 Toray Industries, Inc. Comprimido estable que contiene un derivado de 4,5-epoximorfinano
ES2706407T3 (es) 2009-03-10 2019-03-28 Euro Celtique Sa Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
WO2011052499A1 (ja) * 2009-10-28 2011-05-05 第一三共株式会社 貯蔵安定性が改善された医薬組成物
NZ703564A (en) 2010-03-11 2016-08-26 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
CA2798885C (en) 2010-05-10 2014-11-18 Euro-Celtique S.A. Combination of active loaded granules with additional actives
KR20130030261A (ko) 2010-05-10 2013-03-26 유로-셀티큐 에스.에이. 활성제-무함유 과립 및 그를 포함하는 정제의 제조
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
CA2795324C (en) * 2012-11-09 2015-07-14 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
CA2913331C (en) 2013-06-05 2021-08-24 Pharnext Stable oral solutions for combined api
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CN112716955A (zh) 2013-11-13 2021-04-30 欧洲凯尔特公司 用于治疗疼痛和阿片样物质肠功能障碍综合征的氢吗啡酮和纳洛酮
CN105582011A (zh) * 2014-10-24 2016-05-18 江苏国丹生物制药有限公司 溴甲纳曲酮固体组合物及其制备方法
US10980799B2 (en) 2015-09-24 2021-04-20 Pain Therapeutics, Inc. Crystalline salts of naloxone and naltrexone
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
IL266065B2 (en) * 2016-10-18 2024-03-01 Antheia Inc Methods for preparing benzylisoquinoline alkaloids based on nor-opioid and nel-opioid
WO2018191430A1 (en) * 2017-04-12 2018-10-18 Pavlovich Mike Extended release compositions of opioid antagonists and phosphodiesterase 5 inhibitors
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods
AU2020309829A1 (en) 2019-07-10 2022-01-20 Intas Pharmaceuticals Ltd. Naltrexone formulation
EP4062973A4 (en) * 2019-11-20 2023-11-29 Shionogi & Co., Ltd SOLID FORMULATION CONTAINING 6,7-UNSATURATED-7-CARBAMOYL MORPHINAND DERIVATIVE
WO2022173402A1 (en) * 2021-02-09 2022-08-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising naltrexone hydrochloride

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
WO1993005771A1 (en) * 1991-09-27 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Long-acting preparation
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5697282A (en) * 1994-03-15 1997-12-16 Schuller International, Inc. Apparatus for and method of forming large diameter duct with liner and the product formed thereby
AU2059297A (en) * 1996-03-12 1997-10-01 Alza Corporation Composition and dosage form comprising opioid antagonist
ATE186643T1 (de) 1997-02-14 1999-12-15 Goedecke Ag Stabilisierung von naloxonhydrochlorid
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
PL193273B1 (pl) * 1997-12-22 2007-01-31 Euro Celtique Sa Postać dawkowania doustnego
US6166211A (en) * 1999-03-19 2000-12-26 Endo Pharmaceuticals, Inc. Sequential benzylic oxidations of the naloxone ring system
GB9908921D0 (en) * 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
CN1423559A (zh) * 2000-02-08 2003-06-11 欧罗赛铁克股份有限公司 包含阿片样激动剂和拮抗剂的控释组合物
WO2001085257A2 (en) * 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
DE60232417D1 (de) * 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same

Also Published As

Publication number Publication date
JP5291483B2 (ja) 2013-09-18
EP2289492B1 (en) 2016-12-07
CA2478558C (en) 2012-09-11
CA2748620A1 (en) 2003-09-25
CO5611137A2 (es) 2006-02-28
WO2003077867A2 (en) 2003-09-25
EP1482912A4 (en) 2006-11-15
AU2003220290B2 (en) 2007-06-14
RU2004130441A (ru) 2005-05-20
CN1652752A (zh) 2005-08-10
EP2289492A3 (en) 2011-12-21
ES2616981T3 (es) 2017-06-15
JP4683842B2 (ja) 2011-05-18
MXPA04008772A (es) 2004-12-06
AU2003220290A1 (en) 2003-09-29
US20030229111A1 (en) 2003-12-11
JP2005531515A (ja) 2005-10-20
JP2009143948A (ja) 2009-07-02
KR20040098660A (ko) 2004-11-20
EP2289492A2 (en) 2011-03-02
EP1482912B1 (en) 2011-05-25
CA2478558A1 (en) 2003-09-25
EP1482912A2 (en) 2004-12-08
BR0308452A (pt) 2006-06-06
CA2748620C (en) 2014-03-11
US20170100337A1 (en) 2017-04-13
ATE510534T1 (de) 2011-06-15
WO2003077867A3 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
IL163911A0 (en) Naltrexone hydrochloride compositions
AU154703S (en) Set of trocars
PT1671949E (pt) Piridinilaminas substituídas
EP1560817A4 (en) METHOD AND COMPOSITIONS OF NEW TRIAZINE COMPOUNDS
PL374014A1 (en) Novel phenanthridines having pde 3/4 inhibiting properties
EP1551376A4 (en) IMMUNOMODULATORY COMPOSITIONS, THEIR METHODS OF PREPARATION AND USE
EP1513820A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
IL159599A0 (en) Amine compounds and curable compositions derived therefrom
HK1081957A1 (en) Benzopyranone compounds, compositions thereof, and methods of treatment therewith
IL164581A0 (en) Compounds, compositions and methods
EP1537089A4 (en) CONNECTIONS, COMPOSITIONS AND PROCEDURES
EP1567127A4 (en) METHOD FOR MODIFYING THE RELEASE PROFILE OF COMPRESSED RELATED COMPOSITION COMPOSITIONS
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
EP1673384A4 (en) NITROSED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF USE
EP1551388A4 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME
EP1558083A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
GB0207653D0 (en) Methods of using lamellar bodies for therapeutic purposes
EP1389903A4 (en) FEED ADDITIVE COMPOSITIONS AND METHODS
AP1925A (en) Method for the prevention of malaria
AU2003269192A8 (en) Method for improving or enhancing the appearance of teeth
ZA200502376B (en) Methods and compositions of novel triazine compounds
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
GB0313630D0 (en) Compositions for the enhanced treatment of depression
AU2003266152A8 (en) Compositions for inducing increased levels of beta-chemokines and methods of use therefor